Cargando…
PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966748/ https://www.ncbi.nlm.nih.gov/pubmed/33727604 http://dx.doi.org/10.1038/s41598-021-85289-0 |